A Phase I safety and immunogenicity trial of UBI® microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects

Academic Article

Abstract

  • Thirty-three HIV-seronegative adults were recruited into a Phase I safety and immunogenicity HIV-1 vaccine trial. The immunogens were as follows: a synthetic, monovalent, octameric HIV-1 MN V3 peptide in aluminum hydroxide (alum) adjuvant administered by intramuscular delivery; and a similar product encapsulated in biodegradable micro-spheres composed of co-polymers of lactic and glycolic acids, administered by the oral route. These were administered in three sequential oral doses, followed by a parenteral boost. No serious adverse experiences were observed. Oral administration of this vaccine, alone or in combination with parenteral boosting, resulted in no significant humoral, cellular, or mucosal immune responses. © 2001 Elsevier Science Ltd.
  • Published In

  • Vaccine  Journal
  • Digital Object Identifier (doi)

    Author List

  • Lambert JS; Keefer M; Mulligan MJ; Schwartz D; Mestecky J; Weinhold K; Smith C; Hsieh R; Moldoveanu Z; Fast P
  • Start Page

  • 3033
  • End Page

  • 3042
  • Volume

  • 19
  • Issue

  • 23-24